Is Fabino Enter overvalued or undervalued?

As of 23 September 2025, the valuation grade for Fabino Enter has moved from expensive to very expensive, indicating a significant shift in its perceived market value. The company is currently considered overvalued based on its financial metrics. Key ratios include a PE ratio of 5.09, an EV to EBIT of 6.49, and a Price to Book Value of 1.19, which suggest that the stock is trading at a premium compared to its earnings and book value.
In comparison to its peers, Fabino Enter's valuation appears high, especially when looking at companies like Sun Pharma with a PE ratio of 34.11 and Divi's Lab at 69.64, both of which are categorized as expensive to very expensive. Additionally, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -26.29% compared to the Sensex's positive return of 5.07%. This underperformance further reinforces the conclusion that Fabino Enter is overvalued in the current market environment.